|1.||Ng, Enders Kwok-Wai: 3 articles (08/2010 - 03/2006)|
|2.||Mui, Wilfred Lik-Man: 3 articles (08/2010 - 03/2006)|
|3.||Peker, Yasin: 2 articles (07/2011 - 01/2010)|
|4.||Tsung, Bonnie Yuk-San: 2 articles (08/2010 - 02/2007)|
|5.||Yung, Man Yee: 2 articles (08/2010 - 03/2006)|
|6.||Lam, Chuen Hing: 2 articles (08/2010 - 03/2006)|
|7.||Yau, Phyllis Yin-Ping: 2 articles (02/2007 - 03/2006)|
|8.||Cheng, Angela Yuen-Shan: 2 articles (02/2007 - 03/2006)|
|9.||Larsen, Michael: 1 article (09/2015)|
|10.||Edmundowicz, Steven A: 1 article (09/2015)|
|1.||Weight Loss (Weight Reduction)
03/01/2015 - "The intragastric balloon (IGB) is a temporary, effective and safe endoscopic treatment for weight loss. "
01/01/2010 - "IGB is safe and effective for short-term weight reduction in obese patients. "
02/06/2007 - "IGB is a safe and effective device that achieves moderate weight loss in obese Chinese."
03/01/2006 - "IGB is a safe and effective device that achieves moderate weight loss in obese ethnic Chinese patients."
09/01/2015 - "Based on a meta-analysis of 17 studies including 1683 patients, the percentage of excess weight loss (%EWL) with the Orbera IGB at 12 months was 25.44% (95% confidence interval [CI], 21.47%-29.41%) (random model) with a mean difference in %EWL over controls of 26.9% (95% CI, 15.66%-38.24%; P ≤ .01) in 3 randomized, controlled trials. "
02/01/2009 - "IGB and LAGB are safe and effective treatments for Japanease patients with morbid obesity."
09/01/2001 - "This study evaluated the effectiveness and safety of an intragastric balloon (IGB) for the treatment of morbid obesity. "
06/01/2014 - "Intragastric balloon (IGB) is one of the available options for the management of morbid obesity. "
09/01/2001 - "The IGB represents a useful device for the treatment of morbid obesity, particularly in preparation for definitive antiobesity procedures. "
09/01/2015 - "Our task force consequently recognizes the Orbera IGB for meeting the PIVI criteria for the management of obesity. "
09/01/2015 - "The meta-analyses results indicate that the Orbera IGB meets the PIVI thresholds for both primary and nonprimary bridge obesity therapy. "
04/01/2014 - "One surgical treatment for obesity, available in several countries but not yet approved for use in the United States, is the intragastric balloon (IGB). "
08/01/2013 - "There are limited controlled data for intragastric balloons (IGB) in obesity treatment. "
05/01/2012 - "We discuss the role of the IGB in the treatment of obesity, side effects and the serious complications that can occur."
|5.||Body Weight (Weight, Body)
08/01/2009 - "This study aimed to assess the impact of intragastric balloon (IGB)-induced body weight loss on metabolic syndrome in obese patients and evaluate what happens during 1-year follow-up. "
04/01/2015 - "After 6 months of IGB treatment, there was no significant difference between the reduction in abdominal SCTF and VF, but the results signify a possible correlation between the percentage of body weight loss and the type of abdominal fat reduced, as the impact on the VF was higher when the patients lost >10.0% of their initial weight."
07/01/2014 - "At 0 month, the body weights (BWs) were 121.3±19.0 kg and 127.1±24.4 kg and the VFAs were 299±55 cm2 and 257±56 cm2 in the intensive lifestyle modification therapy group and the IGB therapy group, respectively. "
02/06/2007 - "The BW, BMI, and waist circumference were significantly decreased after the IGB placement (all P < 0.01) with the mean BW loss of (13 +/- 7) kg, mean BMI loss of (5 +/- 3) kg/m(2), mean excessive body weight loss of (45 +/- 36)%, and mean waist circumference loss of (12 +/- 8) cm. 66.7% of the patients were satisfied with the treatment. "
09/01/2015 - "Furthermore, the pooled percentage of total body weight loss (% TBWL) after Orbera IGB implantation was 12.3% (95% CI, 7.9%–16.73%), 13.16% (95% CI, 12.37%–13.95%), and 11.27% (95% CI, 8.17%–14.36%) at 3, 6, and 12 months after implantation, respectively, thus exceeding the PIVI threshold of 5% TBWL for nonprimary (bridge) obesity therapy. "
|4.||Surface Antigens (Surface Antigen)
|6.||Immunoglobulin A (IgA)
|8.||Muromonab-CD3 (Muromonab CD3)
|9.||Proto-Oncogene Proteins p21(ras)
|10.||Monophenol Monooxygenase (Tyrosinase)
|4.||Gastric Bypass (Roux-en-Y Gastric Bypass)